{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:08:37Z","timestamp":1789661317311,"version":"4.0.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"crossref","award":["2021-I2M-1-046"],"award-info":[{"award-number":["2021-I2M-1-046"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15752-6","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:04:46Z","timestamp":1771488286000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The risk of infection-related malignancies and tumor mutational burden in immunocompromised hosts: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Rong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"issue":"1","key":"15752_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.tmaid.2014.12.007","volume":"13","author":"AK Aung","year":"2015","unstructured":"Aung AK, Trubiano JA, Spelman DW. Travel risk assessment, advice and vaccinations in immunocompromised travellers (HIV, solid organ transplant and haematopoeitic stem cell transplant recipients): a review. Travel Med Infect Dis. 2015;13(1):31\u201347.","journal-title":"Travel Med Infect Dis"},{"issue":"5","key":"15752_CR2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1586\/14760584.7.5.663","volume":"7","author":"CN Kotton","year":"2008","unstructured":"Kotton CN. Vaccination and immunization against travel-related diseases in immunocompromised hosts. Expert Rev Vaccines. 2008;7(5):663\u201372.","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"15752_CR3","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.chest.2024.10.054","volume":"167","author":"T Franquet","year":"2024","unstructured":"Franquet T, Raoof S, Lee K, Han J, Gimenez A, Brenes J, Asmar J, Domingo P. Lung nodules and masses in non-HIV immunocompromised patients: a clinical-imaging algorithmic approach. Chest. 2024;167(4):1142\u201360.","journal-title":"Chest"},{"issue":"12","key":"15752_CR4","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1093\/jnci\/djae159","volume":"116","author":"CB Haas","year":"2024","unstructured":"Haas CB, Shiels MS, Pfeiffer RM, D\u2019Arcy M, Luo Q, Yu K, et al. Cancers with epidemiologic signatures of viral oncogenicity among immunocompromised populations in the United States. J Natl Cancer Inst. 2024;116(12):1983\u201391.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"15752_CR5","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","volume":"25","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25(3):486\u2013541.","journal-title":"Cell Death Differ"},{"issue":"2","key":"15752_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41577-020-0390-6","volume":"21","author":"D Dersh","year":"2021","unstructured":"Dersh D, Holl\u00fd J, Yewdell JW. A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion. Nat Rev Immunol. 2021;21(2):116\u201328.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"15752_CR7","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","volume":"8","author":"C de Martel","year":"2020","unstructured":"de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180\u201390.","journal-title":"Lancet Glob Health"},{"issue":"7","key":"15752_CR8","first-page":"646","volume":"46","author":"YT Ji","year":"2024","unstructured":"Ji YT, Liu SW, Zhang YM, Duan HY, Liu XM, Feng ZW, et al. Comparison of the latest cancer statistics, cancer epidemic trends and determinants between China and the United States. Zhonghua Zhong Liu Za Zhi. 2024;46(7):646\u201356.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"2","key":"15752_CR9","doi-asserted-by":"publisher","first-page":"102446","DOI":"10.1016\/j.jceh.2024.102446","volume":"15","author":"SP Singh","year":"2025","unstructured":"Singh SP, Madke T, Chand P. Global epidemiology of hepatocellular carcinoma. J Clin Exp Hepatol. 2025;15(2):102446.","journal-title":"J Clin Exp Hepatol"},{"issue":"6","key":"15752_CR10","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1111\/ajt.14195","volume":"17","author":"CN Kotton","year":"2017","unstructured":"Kotton CN, Huprikar S, Kumar D. Transplant infectious diseases: a review of the scientific registry of transplant recipients published data. Am J Transplant. 2017;17(6):1439\u201346.","journal-title":"Am J Transplant"},{"issue":"9","key":"15752_CR11","doi-asserted-by":"publisher","first-page":"798.e791","DOI":"10.1016\/j.jtct.2021.05.028","volume":"27","author":"J Lindsay","year":"2021","unstructured":"Lindsay J, Kerridge I, Wilcox L, Tran S, O\u2019Brien TA, Greenwood M, et al. Infection-related mortality in adults and children undergoing allogeneic hematopoietic cell transplantation: an Australian registry report. Transplant Cell Ther. 2021;27(9):798.e791-798.e710.","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"15752_CR12","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1093\/ndt\/gfp331","volume":"24","author":"JH Stewart","year":"2009","unstructured":"Stewart JH, Vajdic CM, van Leeuwen MT, Amin J, Webster AC, Chapman JR, et al. The pattern of excess cancer in dialysis and transplantation. Nephrol Dial Transplant. 2009;24(10):3225\u201331.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"15752_CR13","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1001\/jamadermatol.2022.0036","volume":"158","author":"MR Sargen","year":"2022","unstructured":"Sargen MR, Cahoon EK, Yu KJ, Madeleine MM, Zeng Y, Rees JR, et al. Spectrum of nonkeratinocyte skin cancer risk among solid organ transplant recipients in the US. JAMA Dermatol. 2022;158(4):414\u201325.","journal-title":"JAMA Dermatol"},{"issue":"7","key":"15752_CR14","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S1470-2045(24)00189-X","volume":"25","author":"F Jin","year":"2024","unstructured":"Jin F, Vajdic CM, Poynten IM, McGee-Avila JK, Castle PE, Grulich AE. Cancer risk in people living with HIV and solid organ transplant recipients: a systematic review and meta-analysis. Lancet Oncol. 2024;25(7):933\u201344.","journal-title":"Lancet Oncol"},{"issue":"1","key":"15752_CR15","doi-asserted-by":"publisher","first-page":"1848068","DOI":"10.1080\/2162402X.2020.1848068","volume":"9","author":"Z Huo","year":"2020","unstructured":"Huo Z, Li C, Xu X, Ge F, Wang R, Wen Y, et al. Cancer risks in solid organ transplant recipients: results from a comprehensive analysis of 72 cohort studies. Oncoimmunology. 2020;9(1):1848068.","journal-title":"Oncoimmunology"},{"issue":"2","key":"15752_CR16","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/LVT.0000000000000550","volume":"32","author":"D Kahramangil","year":"2024","unstructured":"Kahramangil D, Zarrinpar A, Sahin I. Immune checkpoint inhibitors in the post-transplant landscape of hepatocellular carcinoma: a systematic literature review. Liver Transpl. 2024;32(2):283\u201395.","journal-title":"Liver Transpl"},{"issue":"4","key":"15752_CR17","doi-asserted-by":"publisher","first-page":"100882","DOI":"10.1016\/j.trre.2024.100882","volume":"38","author":"AK Struckmeier","year":"2024","unstructured":"Struckmeier AK, Gosau M, Smeets R. Cutaneous squamous cell carcinoma in solid organ transplant recipients: current therapeutic and screening strategies. Transplant Rev (Orlando). 2024;38(4):100882.","journal-title":"Transplant Rev (Orlando)"},{"issue":"1","key":"15752_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","volume":"7","author":"N Abdel-Wahab","year":"2019","unstructured":"Abdel-Wahab N, Safa H, Abudayyeh A, Johnson DH, Trinh VA, Zobniw CM, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer. 2019;7(1):106.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"15752_CR19","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s40425-019-0639-4","volume":"7","author":"N Abdel-Wahab","year":"2019","unstructured":"Abdel-Wahab N, Safa H, Abudayyeh A, Johnson DH, Trinh VA, Zobniw CM, et al. Corrections to: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer. 2019;7(1):158.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"15752_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.","journal-title":"Genome Med"},{"issue":"2","key":"15752_CR21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202\u20136.","journal-title":"Nat Genet"},{"issue":"7614","key":"15752_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature18945","volume":"536","author":"EM Verdegaal","year":"2016","unstructured":"Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS, et al. Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature. 2016;536(7614):91\u20135.","journal-title":"Nature"},{"key":"15752_CR23","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.","journal-title":"BMJ"},{"issue":"2","key":"15752_CR24","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1634\/theoncologist.2018-0058","volume":"24","author":"WS Liang","year":"2019","unstructured":"Liang WS, Vergilio JA, Salhia B, Huang HJ, Oki Y, Garrido-Laguna I, et al. Comprehensive genomic profiling of Hodgkin lymphoma reveals recurrently mutated genes and increased mutation burden. Oncologist. 2019;24(2):219\u201328.","journal-title":"Oncologist"},{"key":"15752_CR25","unstructured":"Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute; 2011;2(1):1\u201312."},{"issue":"6","key":"15752_CR26","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1177\/0272989X05282643","volume":"25","author":"AE Ades","year":"2005","unstructured":"Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-analysis in decision models. Med Decis Making. 2005;25(6):646\u201354.","journal-title":"Med Decis Making"},{"issue":"3","key":"15752_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"issue":"7109","key":"15752_CR28","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"4","key":"15752_CR29","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088\u2013101.","journal-title":"Biometrics"},{"issue":"3","key":"15752_CR30","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1600-0625.2010.01213.x","volume":"20","author":"KM Thoms","year":"2011","unstructured":"Thoms KM, Kuschal C, Oetjen E, Mori T, Kobayashi N, Laspe P, et al. Cyclosporin A, but not everolimus, inhibits DNA repair mediated by calcineurin: implications for tumorigenesis under immunosuppression. Exp Dermatol. 2011;20(3):232\u20136.","journal-title":"Exp Dermatol"},{"issue":"1","key":"15752_CR31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1600-0625.2011.01413.x","volume":"21","author":"C Kuschal","year":"2012","unstructured":"Kuschal C, Thoms KM, Schubert S, Sch\u00e4fer A, Boeckmann L, Sch\u00f6n MP, et al. Skin cancer in organ transplant recipients: effects of immunosuppressive medications on DNA repair. Exp Dermatol. 2012;21(1):2\u20136.","journal-title":"Exp Dermatol"},{"issue":"25","key":"15752_CR32","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1056\/NEJMra064928","volume":"357","author":"JA Fishman","year":"2007","unstructured":"Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357(25):2601\u201314.","journal-title":"N Engl J Med"},{"issue":"6","key":"15752_CR33","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/01.TP.0000436907.56425.5c","volume":"97","author":"SN Sherston","year":"2014","unstructured":"Sherston SN, Carroll RP, Harden PN, Wood KJ. Predictors of cancer risk in the long-term solid-organ transplant recipient. Transplantation. 2014;97(6):605\u201311.","journal-title":"Transplantation"},{"issue":"5","key":"15752_CR34","doi-asserted-by":"publisher","first-page":"e1002024","DOI":"10.1371\/journal.pmed.1002024","volume":"13","author":"L Fardet","year":"2016","unstructured":"Fardet L, Petersen I, Nazareth I. Common infections in patients prescribed systemic glucocorticoids in primary care: a population-based cohort study. PLoS Med. 2016;13(5):e1002024.","journal-title":"PLoS Med"},{"issue":"11","key":"15752_CR35","doi-asserted-by":"publisher","first-page":"e2342006","DOI":"10.1001\/jamanetworkopen.2023.42006","volume":"6","author":"E Kolla","year":"2023","unstructured":"Kolla E, Weill A, Zaidan M, De Martin E, Colin De Verdiere S, Semenzato L, et al. COVID-19 hospitalization in solid organ transplant recipients on immunosuppressive therapy. JAMA Netw Open. 2023;6(11):e2342006.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"15752_CR36","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s40262-012-0007-8","volume":"51","author":"TK Bergmann","year":"2012","unstructured":"Bergmann TK, Barraclough KA, Lee KJ, Staatz CE. Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation. Clin Pharmacokinet. 2012;51(11):711\u201341.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"15752_CR37","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/php.12318","volume":"91","author":"M Ming","year":"2015","unstructured":"Ming M, Zhao B, Qiang L, He YY. Effect of immunosuppressants tacrolimus and mycophenolate mofetil on the keratinocyte UVB response. Photochem Photobiol. 2015;91(1):242\u20137.","journal-title":"Photochem Photobiol"},{"issue":"1","key":"15752_CR38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","volume":"14","author":"XH Zhang","year":"2021","unstructured":"Zhang XH, Chen J, Han MZ, Huang H, Jiang EL, Jiang M, et al. The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol. 2021;14(1):145.","journal-title":"J Hematol Oncol"},{"issue":"23","key":"15752_CR39","doi-asserted-by":"publisher","first-page":"5949","DOI":"10.3390\/cancers14235949","volume":"14","author":"M Markouli","year":"2022","unstructured":"Markouli M, Ullah F, Omar N, Apostolopoulou A, Dhillon P, Diamantopoulos P, et al. Recent advances in adult post-transplant lymphoproliferative disorder. Cancers (Basel). 2022;14(23):5949.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"15752_CR40","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMra1702693","volume":"378","author":"D Dierickx","year":"2018","unstructured":"Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults. N Engl J Med. 2018;378(6):549\u201362.","journal-title":"N Engl J Med"},{"issue":"5","key":"15752_CR41","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1200\/JCO.20.01801","volume":"39","author":"AT O'Neill","year":"2021","unstructured":"O\u2019Neill AT, Chakraverty R. Graft versus leukemia: current status and future perspectives. J Clin Oncol. 2021;39(5):361\u201372.","journal-title":"J Clin Oncol"},{"key":"15752_CR42","doi-asserted-by":"publisher","first-page":"15035","DOI":"10.1038\/nrdp.2015.35","volume":"1","author":"SG Deeks","year":"2015","unstructured":"Deeks SG, Overbaugh J, Phillips A, Buchbinder S. HIV infection. Nat Rev Dis Primers. 2015;1:15035.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"15752_CR43","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1186\/s12890-024-03362-6","volume":"24","author":"C Li","year":"2024","unstructured":"Li C, He H, Wang Y, Huang L, Chen Z, Zhang Q, et al. Outcomes and inflammation changes in different types of immunocompromised patients with critically ill COVID-19 admitted to ICU: a national multicenter study. BMC Pulm Med. 2024;24(1):548.","journal-title":"BMC Pulm Med"},{"issue":"11","key":"15752_CR44","first-page":"3615","volume":"109","author":"M Baron","year":"2024","unstructured":"Baron M, Labreche K, Veyri M, D\u00e9sir\u00e9 N, Bouzidi A, Seck-Thiam F, et al. Epstein-Barr virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments. Haematologica. 2024;109(11):3615\u201330.","journal-title":"Haematologica"},{"issue":"12","key":"15752_CR45","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1200\/JCO.2012.45.2524","volume":"31","author":"RA Nelson","year":"2013","unstructured":"Nelson RA, Levine AM, Bernstein L, Smith DD, Lai LL. Changing patterns of anal canal carcinoma in the United States. J Clin Oncol. 2013;31(12):1569\u201375.","journal-title":"J Clin Oncol"},{"issue":"5742","key":"15752_CR46","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1126\/science.1114233","volume":"309","author":"P O'Donovan","year":"2005","unstructured":"O\u2019Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science. 2005;309(5742):1871\u20134.","journal-title":"Science"},{"issue":"1","key":"15752_CR47","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1038\/s41467-018-06027-1","volume":"9","author":"GJ Inman","year":"2018","unstructured":"Inman GJ, Wang J, Nagano A, Alexandrov LB, Purdie KJ, Taylor RG, et al. The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature. Nat Commun. 2018;9(1):3667.","journal-title":"Nat Commun"},{"issue":"1","key":"15752_CR48","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13046-022-02258-9","volume":"41","author":"S Citro","year":"2022","unstructured":"Citro S, Miccolo C, Medda A, Ghiani L, Tagliabue M, Ansarin M, et al. HPV-mediated regulation of SMAD4 modulates the DNA damage response in head and neck cancer. J Exp Clin Cancer Res. 2022;41(1):59.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"15752_CR49","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1002\/jmv.26780","volume":"93","author":"L Barrett","year":"2021","unstructured":"Barrett L, Dai L, Wang S, Qin Z. Kaposi\u2019s sarcoma-associated herpesvirus and extracellular vesicles. J Med Virol. 2021;93(6):3294\u20139.","journal-title":"J Med Virol"},{"issue":"5","key":"15752_CR50","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/cr.2011.5","volume":"21","author":"D Liang","year":"2011","unstructured":"Liang D, Gao Y, Lin X, He Z, Zhao Q, Deng Q, et al. A human herpesvirus miRNA attenuates interferon signaling and contributes to maintenance of viral latency by targeting IKK\u03b5. Cell Res. 2011;21(5):793\u2013806.","journal-title":"Cell Res"},{"issue":"9","key":"15752_CR51","doi-asserted-by":"publisher","first-page":"e29071","DOI":"10.1002\/jmv.29071","volume":"95","author":"DA Davis","year":"2023","unstructured":"Davis DA, Shrestha P, Yarchoan R. Hypoxia and hypoxia-inducible factors in Kaposi sarcoma-associated herpesvirus infection and disease pathogenesis. J Med Virol. 2023;95(9):e29071.","journal-title":"J Med Virol"},{"issue":"1","key":"15752_CR52","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41392-023-01434-3","volume":"8","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Li H, Du H, Yin Z, He M, Fan J, et al. A Kaposi\u2019s sarcoma-associated herpes virus-encoded microRNA contributes to dilated cardiomyopathy. Signal Transduct Target Ther. 2023;8(1):226.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"15752_CR53","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nrc2888","volume":"10","author":"EA Mesri","year":"2010","unstructured":"Mesri EA, Cesarman E, Boshoff C. Kaposi\u2019s sarcoma and its associated herpesvirus. Nat Rev Cancer. 2010;10(10):707\u201319.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"15752_CR54","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/hel.12131","volume":"19","author":"DT Nevin","year":"2014","unstructured":"Nevin DT, Morgan CJ, Graham DY, Genta RM. Helicobacter pylori gastritis in HIV-infected patients: a review. Helicobacter. 2014;19(5):323\u20139.","journal-title":"Helicobacter"},{"issue":"3","key":"15752_CR55","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/jebm.12252","volume":"10","author":"W Cheungpasitporn","year":"2017","unstructured":"Cheungpasitporn W, Thongprayoon C, Wijarnpreecha K, Mitema DG, Mao MA, Nissaisorakarn P, et al. Decline in prevalence and risk of helicobacter pylori in kidney transplant recipients: a systematic review and meta-analysis. J Evid Based Med. 2017;10(3):171\u20136.","journal-title":"J Evid Based Med"},{"issue":"3","key":"15752_CR56","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00262-017-2099-3","volume":"67","author":"JC Becker","year":"2018","unstructured":"Becker JC, Stang A, Hausen AZ, Fischer N, DeCaprio JA, Tothill RW, et al. Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC. Cancer Immunol Immunother. 2018;67(3):341\u201351.","journal-title":"Cancer Immunol Immunother"},{"key":"15752_CR57","doi-asserted-by":"publisher","first-page":"102296","DOI":"10.1016\/j.ctrv.2021.102296","volume":"100","author":"E Bardi","year":"2021","unstructured":"Bardi E, Mulder RL, van Dalen EC, Bhatt NS, Ruble KA, Burgis J, et al. Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: recommendations from the international late effects of childhood cancer guideline harmonization group. Cancer Treat Rev. 2021;100:102296.","journal-title":"Cancer Treat Rev"},{"issue":"25","key":"15752_CR58","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500\u20131.","journal-title":"N Engl J Med"},{"key":"15752_CR59","doi-asserted-by":"publisher","first-page":"1050876","DOI":"10.3389\/fimmu.2022.1050876","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Lin J, You Z, Tu H, He P, Li J, et al. Cancer risks in rheumatoid arthritis patients who received immunosuppressive therapies: will immunosuppressants work? Front Immunol. 2022;13:1050876.","journal-title":"Front Immunol"},{"issue":"2","key":"15752_CR60","doi-asserted-by":"publisher","first-page":"e003026","DOI":"10.1136\/jitc-2021-003026","volume":"10","author":"RI Haddad","year":"2022","unstructured":"Haddad RI, Seiwert TY, Chow LQM, Gupta S, Weiss J, Gluck I, et al. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. J Immunother Cancer. 2022;10(2):e003026.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"15752_CR61","doi-asserted-by":"publisher","first-page":"13404","DOI":"10.1038\/s41598-019-49771-0","volume":"9","author":"J Wang","year":"2019","unstructured":"Wang J, Sun H, Zeng Q, Guo XJ, Wang H, Liu HH, et al. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma. Sci Rep. 2019;9(1):13404.","journal-title":"Sci Rep"},{"issue":"4","key":"15752_CR62","doi-asserted-by":"publisher","first-page":"864","DOI":"10.20892\/j.issn.2095-3941.2020.0370","volume":"17","author":"KA Szymonowicz","year":"2020","unstructured":"Szymonowicz KA, Chen J. Biological and clinical aspects of HPV-related cancers. Cancer Biol Med. 2020;17(4):864\u201378.","journal-title":"Cancer Biol Med"},{"key":"15752_CR63","doi-asserted-by":"publisher","first-page":"101923","DOI":"10.1016\/j.tranon.2024.101923","volume":"44","author":"Z Lu","year":"2024","unstructured":"Lu Z, Fan P, Huo W, Feng Y, Wang R. Genomic profiles and their relationships with clinical characteristics and immune features in cervical cancer. Transl Oncol. 2024;44:101923.","journal-title":"Transl Oncol"},{"issue":"3","key":"15752_CR64","doi-asserted-by":"publisher","first-page":"e15292","DOI":"10.1111\/dth.15292","volume":"35","author":"LE Hernandez","year":"2022","unstructured":"Hernandez LE, Mohsin N, Yaghi M, Frech FS, Dreyfuss I, Nouri K. Merkel cell carcinoma: an updated review of pathogenesis, diagnosis, and treatment options. Dermatol Ther. 2022;35(3):e15292.","journal-title":"Dermatol Ther"},{"issue":"6","key":"15752_CR65","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.annonc.2024.03.007","volume":"35","author":"X Wang","year":"2024","unstructured":"Wang X, Lamberti G, Di Federico A, Alessi J, Ferrara R, Sholl ML, et al. Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities. Ann Oncol. 2024;35(6):508\u201322.","journal-title":"Ann Oncol"},{"issue":"5","key":"15752_CR66","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1158\/1078-0432.CCR-20-3054","volume":"27","author":"JH Strickler","year":"2021","unstructured":"Strickler JH, Hanks BA, Khasraw M. Tumor mutational burden as a predictor of immunotherapy response: is more always better? Clin Cancer Res. 2021;27(5):1236\u201341.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"15752_CR67","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1001\/jamaoncol.2025.2374","volume":"11","author":"N Saleem","year":"2025","unstructured":"Saleem N, Wang J, Rejuso A, Teixeira-Pinto A, Stephens JH, Wilson A, et al. Outcomes of solid organ transplant recipients with advanced cancers receiving immune checkpoint inhibitors: a systematic review and individual participant data meta-analysis. JAMA Oncol. 2025;11(10):1150\u20139.","journal-title":"JAMA Oncol"},{"issue":"7","key":"15752_CR68","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.ajt.2025.01.044","volume":"25","author":"DB Kaufman","year":"2025","unstructured":"Kaufman DB, Akkina SK, Stegall MD, Piper JB, Gaber AO, Asch WS, et al. Induction of immune tolerance in living related human leukocyte antigen-matched kidney transplantation: a phase 3 randomized clinical trial. Am J Transplant. 2025;25(7):1461\u201370.","journal-title":"Am J Transplant"},{"issue":"4","key":"15752_CR69","doi-asserted-by":"publisher","first-page":"406","DOI":"10.6004\/jnccn.2022.7009","volume":"20","author":"AJ Portuguese","year":"2022","unstructured":"Portuguese AJ, Tykodi SS, Blosser CD, Gooley TA, Thompson JA, Hall ET. Immune checkpoint inhibitor use in solid organ transplant recipients: a systematic review. J Natl Compr Canc Netw. 2022;20(4):406-416.e411.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"15752_CR70","doi-asserted-by":"publisher","first-page":"e002097","DOI":"10.1136\/jitc-2020-002097","volume":"9","author":"K Lurain","year":"2021","unstructured":"Lurain K, Ramaswami R, Mangusan R, Widell A, Ekwede I, George J, Ambinder R, Cheever M, Gulley JL, Goncalves PH, et al. Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin\u2019s lymphoma. J Immunother Cancer. 2021;9(2):e002097.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"15752_CR71","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","volume":"30","author":"TA Chan","year":"2019","unstructured":"Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44\u201356.","journal-title":"Ann Oncol"},{"issue":"11","key":"15752_CR72","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1038\/bjc.2017.106","volume":"116","author":"H Freisling","year":"2017","unstructured":"Freisling H, Arnold M, Soerjomataram I, O\u2019Doherty MG, Ord\u00f3\u00f1ez-Mena JM, Bamia C, et al. Comparison of general obesity and measures of body fat distribution in older adults in relation to cancer risk: meta-analysis of individual participant data of seven prospective cohorts in Europe. Br J Cancer. 2017;116(11):1486\u201397.","journal-title":"Br J Cancer"},{"issue":"11","key":"15752_CR73","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1007\/s00134-024-07647-6","volume":"50","author":"G Dumas","year":"2024","unstructured":"Dumas G, Joseph A, Zafrani L. Diagnostic tests for infections in critically ill immunocompromised patients. Intensive Care Med. 2024;50(11):1920\u20132.","journal-title":"Intensive Care Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15752-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15752-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15752-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T11:02:48Z","timestamp":1774522968000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15752-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15752"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15752-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"406"}}